Abstract
Triple-negative breast cancer (TNBC) (ER−/PGR−/erb-2−) constitutes an aggressive subtype in breast cancer because it is accompanied by a significant decrease in overall survival (OAS) and recurrence-free survival (RFS) compared with hormone receptor positive breast cancers. This retrospective cohort study investigates the following issues: (1) Is there an impact of guideline-adherent treatment on RFS and OAS in TNBC? (2) Which adjuvant treatment has the most important impact on RFS and OAS in TNBC? This German retrospective multi-centre cohort study included 3,658 patients with primary breast cancer recruited from 2000 to 2005. The definition of guideline adherence was based on the German national S3 guideline for diagnosis and treatment of breast cancer (2004). A total of 371 patients (10.1%) had TNBC. Compared with HR+/erb-2− breast cancer (P = 0.001; HR = 1.75; 95% CI: 1.27–2.40), the recurrence rate of TNBC was significantly higher (P < 0.001; HR = 2.86; 95% CI: 2.17–3.76). Furthermore, the 5-year RFS and OAS was significantly lower in TNBC (RFS: 74.8% [95% CI: 68.8–80.8%] vs. 86.5% [95% CI: 84.6–88.4%] [log-rank P = 0.0001]) (OAS: 75.8% [95% CI: 69.9–81.8%] vs. 86.0% [95% CI: 84.1–87.9%] [log-rank P = 0.0001]). The most important parameters predicting RFS and OAS in TNBC after receiving guideline-conform chemotherapy are guideline-adherent surgery, radiotherapy, nodal status and grading. Overall, 66.8% TNBC were found with one or more (18%) guideline violations, which subsequently impaired OAS and RFS. The most important impact on OAS and RFS in TNBC patients was because of guideline violations (GV) concerning adjuvant radiotherapy and GV concerning adjuvant chemotherapy. Patients with TNBC primarily have a worse prognosis in terms of RFS and OAS than patients of a primarily non-TNBC phenotype. There is a strong association between guideline-adherent adjuvant treatment and improved survival outcome in TNBC. The outcome significantly decreases with the number of guideline violations.
Similar content being viewed by others
References
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157–167
Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41(1):40–47
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32
Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(1):1–11
Teng YH, Thike AA, Wong NS, Tan PH (2011) Therapeutic targets in triple negative breast cancer: where are we now? Recent Pat Anticancer Drug Discov 6(2):196–209
Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3):627–636
Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140
Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, Wischnewsky MB, Wöckel A (2011) A comparison of international breast cancer guidelines: do the national guidelines differ in treatment recommendations? Eur J Cancer doi:10.1016/j.ejca.2011.06.020
Kreienberg R, Kopp I, Lorenz W, Budach W, Dunst J, Lebeau A et al. (2004) Guidelines for diagnosis and treatment for breast cancer in women. National Cancer Society 2004
Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. N Engl J Med 363(20):1938–1948
Chacon RD, Costanzo MV (2010) Triple negative breast cancer. Breast Cancer Res 12(2):S3
Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683–692
Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE et al (2008) Get with guidelines: stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119(1):107–115
Wöckel A, Kurzeder C, Geyer V, Novopashenny I, Wolters R, Wischnewsky M et al (2010) Effects of guideline adherence in primary breast cancer: a 5 year multi-center cohort study of 3976 patients. Breast 19:120–127
Hamaker ME, Schreurs WH, Uppelschoten JM, Smorenburg CH (2009) Breast cancer in the elderly: retrospective study on diagnosis and treatment according to national guidelines. Breast J 15:26–33
Varga D, Wischnewsky M, Atassi Z, Wolters R, Geyer V, Strunz K, Kreienberg R, Woeckel A (2010) Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology 78(3–4):189–195
Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D, Blettner M, Kreienberg R (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–753
Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodal negative breast cancer. J Clinical Oncol 22:3685–3693
Acknowledgments
This study was supported by the German Federal Ministry of Education and Research (BMBF-Grant-01ZP0505). This study and the project BRENDA have been approved by the ethics committee of the University of Ulm. We gratefully thank the following people for their contributions to the BRENDA study: Karsten Gnauert (Ostalbklinikum, Aalen), Steffen Fritz (Kreisklinik Biberach), Ulf Göretzlehner (Kreiskrankenhaus Ehingen), Hans-Walter Vollert (Städt. Krankenhaus Friedrichshafen), Peter Jakob Albert (Klinikum Heidenheim), Ricardo Felberbaum (Klinikum Kempten), Andreas Zorr (Klinikum Konstanz), Felix Flock (Klinikum Memmingen), Erik Schlicht (Stauferklinik, Mutlangen), Martina Gropp-Meier (Oberschwabenklinik Ravensburg), Gerhard Bartzke (Kreiskrankenhaus Rottweil), Andreas Rempen (Diakonie-Krankenhaus, Schwäbisch Hall), Edgar Schelble (Kreiskrankenhaus Sigmaringen), Theodor Dinkelacker (Helfenstein-Klinik Geislingen), Andreas Grüneberger (Oberschwabenklinik Wangen) and Thorsten Kühn (Städt. Kliniken, Esslingen).
Conflict of interest
All authors declare that there are no potential conflicts of interest, including any financial, personal or other relationships with other people or organizations within that could inappropriately influence this work.
Author information
Authors and Affiliations
Corresponding author
Additional information
L. Schwentner and R. Wolters have contributed equally to this work.
This study was conducted on behalf of the BRENDA study group.
Rights and permissions
About this article
Cite this article
Schwentner, L., Wolters, R., Koretz, K. et al. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study. Breast Cancer Res Treat 132, 1073–1080 (2012). https://doi.org/10.1007/s10549-011-1935-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-011-1935-y